NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients’ quality of life. NGX-1998—Topical Liquid High-Concentration Capsaicin NGX-1998 is a topical liquid formulation containing a high concentration of capsaicin, the active ingredient in Qutenza. The formulation contains a 20% concentration of capsaicin in a semi viscous solution which includes a mixture of penetration enhancers. NGX-1998 is being developed to be applied using a sponge applicator that would provide for a predictable and reproducible delivery of the solution to the treatment area. NGX-1998 would be applied directly to the painful area by a healthcare professional and left on the skin for approximately five minutes, after which, the skin would be cleansed using a proprietary cleansing gel. Qutenza Qutenza is a non-narcotic analgesic formulated in a localized treatment patch containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. Qutenza can be used alone or in conjunction with other pain medications and as such may have place as first line or additive therapy. Qutenza was approved by the U.S. Food and Drug Administration (FDA) in 2009 for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. In 2009, the company entered into the Astellas Pharma Europe Ltd. (Astellas) Agreement, under which Astellas was granted an exclusive license to promote, distribute and market Qutenza in the Licensed Territory. As of December 31, 2011, Qutenza was commercially available in 21 European countries in the Astellas Territory. Other Product Development Programs The company’s portfolio consists of the Acetaminophen Prodrugs for traumatic pain, post-surgical pain and fever. Suppliers The company’s suppliers include LTS Lohmann Therapie-Systeme AG, Formosa Laboratories, Inc, and Contract Pharmaceuticals Limited Canada. Strategy The company intends to utilize its development and commercial expertise to become a sustainable specialty pain management company. Main elements of its strategy for achieving this goal include advance the development of NGX-1998 rapidly and with a broad neuropathic pain focus; maintain market availability of Qutenza and seek potential opportunities for label expansion; explore opportunities to augment development and commercialization activities through strategic alliances and collaborations; and expand product portfolio. Regulations Any products that the company manufactures or distributes under FDA approvals are subject to pervasive and continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the products. History NeurogesX, Inc. was founded in 1998. The company was incorporated in California as Advanced Analgesics, Inc. in 1998 and changed its name to NeurogesX, Inc. in 2000. In 2007, the company reincorporated into Delaware.
neurogesx inc (NGSX:OTC US)
2215 Bridgepointe Parkway
San Mateo, CA 94404
|POZEN Inc||$6.91 USD||-0.17|
|Sunesis Pharmaceuticals Inc||$2.36 USD||+0.02|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact NEUROGESX INC, please visit www.neurogesx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.